Naurex to Present at UBS Global Healthcare Conference

EVANSTON, Ill., May 15, 2014 /PRNewswire/ -- Naurex Inc. today announced that its president and chief executive officer, Norbert G. Riedel, PhD, will present at the UBS Global Healthcare Conference on Monday, May 19, 2014 at 1:00 p.m. EDT. Dr. Riedel will provide an overview of the company and discuss its two clinical-stage rapid-acting antidepressant drug candidates, GLYX-13 and NRX-1074.

Last week Naurex reported positive top-line Phase 2b results for GLYX-13 and the advancement of NRX-1074 into a Phase 2 depression study. The company also announced that existing shareholders invested an additional $25 million in the company.

The UBS Global Healthcare Conference will be held May 19-21, 2014 at the Sheraton New York Times Square Hotel in New York City.  For more information, visit

About Naurex Inc.
Naurex is a biopharmaceutical company developing novel modulators of the NMDA receptor to treat challenging diseases of the central nervous system (CNS). The company's first-generation compound, GLYX-13, is in development as adjunctive therapy for patients with difficult-to-treat depression. GLYX-13 has shown rapid-acting and robust antidepressant activity in Phase 2 clinical studies and has been well tolerated with none of the psychotomimetic side effects that limit other drugs and mechanisms targeting the NMDA receptor. Naurex's second-generation compound, NRX-1074, is an orally active agent in Phase 2 clinical development for the treatment of major depressive disorder. These lead programs stem from the company's proprietary platform for discovering compounds that work through a novel mechanism, selectively modulating subtypes of the NMDA receptor to affect pathways involved with neuroplasticity. This mechanism has therapeutic potential in a number of CNS indications with high unmet medical needs. For more information, visit

Company Contact: 

Media Contacts:

Naurex Inc.

BLL Partners, LLC

Ashish Khanna

Barbara Lindheim

Vice President, Corporate Development



White Oak Communications, Inc.

Jed Weiner


SOURCE Naurex Inc.


More by this Source

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.


PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.